911285 = 798618 - 500 Beiträge pro Seite

[dosco12]

911285 = 798618

anbei eine info die auch dem letzten zweifler sicherheit geben muss (brief vom CFO):


_________________________________-

Dear ,

Re: MIV Therapeutics, Inc. Regulation S shares


Thank you for your inquiries regarding the resale of your Regulation S shares. Your shares may be resold in the United States on the OTC Bulletin Board, subject to certain hold periods and manner of sale requirements.



Rule 144 of the Securities Act of 1933 applies to the resale of these shares. Rule 144 of the Securities Act of 1933 states that when an unaffiliated investor has held shares originally purchased pursuant to an exemption from registration for a period of at least one year, then an amount of shares of not more than 1% of the total issued and outstanding amount of shares of the Company may be sold through a broker within each 90 day period.



In order to remove the legend from your shares to make them freely tradeable you will be required to obtain a legal opinion on the tradeability of these shares. You are responsible for all costs associated with the legal opinion and any broker fees that may be incurred. When the Company receives this legal opinion along with the complete 144 paperwork, it will authorize the removal of the legend so that the shares may be traded in the United States.



Alternatively, if you have held the shares for a total of two years, then the legend can be removed with no manner of sale requirement. Rule 144(k) of the Act states that when an unaffiliated investor has held shares originally purchased pursuant to an exemption from registration for a period of at least two years, the shares may be freely sold without restriction. Currently the Company’s transfer agent requires a letter confirming a shareholder’s non affiliate status and stating the shareholder has held the shares for more than two years. While the transfer agent does not currently require a legal opinion for removing a legend from shares more than two years old, that requirement may change in the future and it is recommended that you contact the transfer agent directly to confirm their present requirements. The Company’s transfer agent is:



Interwest Transfer Co. Inc.

1981 East 4800 South, Suite 100

Salt Lake City, Utah 84117

Tel. [phone]



The procedure to sell the shares on the OTCBB would be to withdraw the shares from your brokerage account and obtain the original stock certificate, which then must be then held for a minimum of one year before you can resell the shares pursuant to Rule 144. If you are able to obtain a letter from your brokerage firm or investment company certifying that the shares were purchased on a specific date and that they have not traded since that date, then you will be able to get credit for that time to go towards the one or two year holding period.



Note that the Company currently has no plans to withdraw the Regulation S shares from the Berlin or Frankfurt exchanges. It is not uncommon for companies with multi-listed shares to be trading for different prices on different exchanges. In addition, these exchanges do not allow for the unilateral delisting of shares from their exchange.



I trust the foregoing has addressed your concerns.



Please do not hesitate to contact us should you require any further information.



Sincerely yours,



Pat McGowan

CFO

MIV Therapeutics, Inc

[Woodly2712]

[dosco12]

Wednesday October 19, 12:46 pm ET


MIV Therapeutics Wins 2005 Frost & Sullivan Award for Technology Innovation in the Field of Advanced Medical Coatings

[dosco12]

NEWS

Friday October 21, 3:30 am ET

MIV Therapeutics Officially Named Winner of Prestigious Award for Innovation in Advanced Biomedical Technology

Frost & Sullivan Report Praises MIVT Proprietary Biocompatible Coating Technology for Stents and Other Biomedical Devices

VANCOUVER, British Columbia--(BUSINESS WIRE)--Oct. 21, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News; FWB:MIV), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has officially been named winner of Frost & Sullivan`s prestigious 2005 Award for Technology Innovation in the Field of Advanced Medical Coatings.
ADVERTISEMENT


A report by Frost & Sullivan about the award and MIVT`s proprietary technology can be viewed at: http://www.trilogy-capital.com/tcp/mivt/frost.html.

The Frost & Sullivan award recognizes MIVT`s pioneering work to develop proprietary coating technologies that may enable the production of better, safer vascular stents, medical devices and drug delivery systems. In the award notification, Frost & Sullivan praises MIVT for its development of two distinctive routes for fabricating leading-edge biocompatible coatings for stents. The notification report also explains in detail the substantial competitive advantages of these technologies in the global biomedical marketplace.

MIVT`s proprietary technologies have been shown not to trigger a variety of the adverse reactions often associated with currently available polymer-coated coronary stents, including the re-blocking of arteries following angioplasty and thrombosis (blood clotting). MIVT coatings are based on a natural material, Hydroxyapatite (HAp), a component of hard tissue found in human teeth and bone, which enables the surface of metallic stents to virtually mimic the biological "signature" of natural tissue. MIVT believes its innovative technology also has the potential for an array of additional biomedical applications, including dental, hip and bone repair implants.

Each year Frost & Sullivan presents an award to one company or individual whose innovative research is expected to bring significant contributions to the industry. The award criteria recognize the quality and depth of a company`s research and development program, as well as the vision and risk-taking that enabled it to undertake such an endeavor.

[dosco12]

10QSB [html][text] 135 KB Optional form for quarterly and transition reports of small business issuers 2005-10-24 000-30453


zudem info über smt übernahme!!!



3. STOCKHOLDERS` EQUITY

(a) Common Stock

(i) During the three month period ended August 31, 2005,
a total of 1,704,689 Reg S stock has been issued at
a price range of $0.30 to $0.51 per share for total
net proceeds of $720,095 (net of agent`s fees of
$75,500).

As at August 31, 2005, 2,500,000 Regulation S stocks
are held in trust by the financial custodian.

(ii) During the three month period ended August 31, 2005,
the Company issued an aggregate of 531,342 common
shares for consulting, research and development,
legal and employee services for a total value of
$252,684 being the fair value of the shares at the
earlier of 1) the agreement date and 2) the period of
completion of performance. Of these shares, 116,071
shares were issued for total value of $65,000 being
the remaining balance of SagaX, Inc. debt which the
Company has agreed to pay as part of the Acquisition
Agreement.

(iii) During the three month period ended August 31, 2005,
the Company issued 1,668,481 common shares pursuant
to an exercise of stock purchase warrants for total
proceeds of $911,900. An additional 25,000 was
exercised for total value of $16,500 which was
recorded as common stock issuable and was issued
subsequent to August 31, 2005.


F-7

<PAGE>

MIV THERAPEUTICS INC.
(A development stage company)

Notes to Consolidated Financial Statements
August 31, 2005
(Unaudited - Prepared by Management)
(EXPRESSED IN U.S. DOLLARS)
- --------------------------------------------------------------------------------


3. STOCKHOLDERS` EQUITY (continued)

(iv) On August 11, 2005, the Company completed a private
placement of 7,545,000 units at the price of $0.45
per Unit for total net proceeds of $3,370,250. Each
Unit is comprised of one common share together with
one-half of one Series "A" non-transferable share
purchase warrant (each a "Series A Warrant") and
one-half of one Series "B" non-transferable share
purchase warrant (each a "Series B Warrant"). Each
whole Series A Warrant entitles the holder to
purchase one common share at a price of $0.65 per
share for a period which is the earlier of (i) 12
months from August 11, 2005 and (ii) six months
commencing from the effective date of the Company`s
proposed "Registration Statement". Each whole Series
B Warrant entitles the holder to purchase one common
share at a price of $0.70 per share for the first 12
months, at a price of $0.85 per share for the next 6
months, and at a price of $1.00 per share for the
last 6 months thereafter. Series B Warrants are
exercisable at the earlier of (i) 30 months from
August 11, 2005 and (ii) 24 months commencing from
the effective date of the Company`s proposed
"Registration Statement". In connection to the
private placement, a finder`s fee comprised of
$25,000 in cash was accrued and 62,500 Series A
Warrants and Series B Warrants were issued. As well,
39,994 units and 100,000 units were issued for legal
fees and investor relations services, respectively.

As at August 31, 2005, these warrants had an
estimated fair value of $2,245,749 using the Black
Scholes Option Pricing Model.

F-8



<PAGE>

MIV THERAPEUTICS INC.
(A development stage company)

Notes to Consolidated Financial Statements
August 31, 2005
(Unaudited - Prepared by Management)
(EXPRESSED IN U.S. DOLLARS)
- --------------------------------------------------------------------------------

3. STOCKHOLDERS` EQUITY (continued)

(b) Warrants

The following table summarizes information about the warrants
issued by the Company:
<TABLE>
Weighted
Average
Number of Shares Exercise price
---------------------------------
<S> <C> <C>
Balance, May 31, 2004 9,386,449 0.60

Issued - convertible debentures 1,851,500 0.25
Issued - finders` fees 10,000 0.75
Issued - services rendered 5,270,000 0.32
Exercised (2,310,710) 0.26
Expired (7,043,220) 0.65
---------------------------------

Balance, May 31, 2005 - Regular 7,164,019 0.45
Balance, May 31, 2005 - Series "A" 3,374,999 0.66
Balance, May 31, 2005 - Series "C" 674,997 0.66
---------------------------------

Balance, May 31, 2005 11,214,015 0.53

Regular:
Issued - services rendered 825,000 0.50
Exercised (409,290) 0.26
Series "A":
Issued - private placement 3,842,498 0.65
Issued - finder`s fee 62,500 0.65
Exercised (1,152,933) 0.66
Series "B":
Issued - private placement 3,842,498 0.85
Issued - finder`s fee 62,500 0.85
Series "C":
Exercised (135,000) 0.66
---------------------------------

Balance, August 31, 2005 - Regular 7,579,729 0.46
Balance, May 31, 2005 and 2004 - Series "A" 6,127,064 0.65
Balance, May 31, 2005 and 2004 - Series "B" 3,904,998 0.85
Balance, May 31, 2005 and 2004 - Series "C" 539,997 0.66
---------------------------------

BALANCE, AUGUST 31, 2005 18,151,788 0.61
=================================
</TABLE>

F-9

<PAGE>

MIV THERAPEUTICS INC.
(A development stage company)

Notes to Consolidated Financial Statements
August 31, 2005
(Unaudited - Prepared by Management)
(EXPRESSED IN U.S. DOLLARS)
- --------------------------------------------------------------------------------


3. STOCKHOLDERS` EQUITY (continued)

(c) Stock Options

The Company`s incentive stock options plan provides for the
grant of incentive stock options for up to 5,000,000 common
shares to employees, consultants, officers and directors of
the Company. Incentive benefits granted under the plan may be
either incentive stock options, non-qualified stock options,
stock awards, restricted shares or cash awards. Options are
granted for a term not to exceed five years from the date of
grant. Stock options granted generally vest over a period of
two years.

During the period ended August 31, 2005, the Company granted
200,000 stock options to a director of the Company with an
exercise price of $0.30 per share being vested immediately and
with an expiry date five years from date of grant.

The fair value of the option granted is estimated on the grant
date using the Black-Scholes option pricing model assuming no
dividend yield and the following weighted average assumptions:

August 31 May 31
2005 2005

Risk-free interest rate 3.50% 3.50%
Expected life (in years) 5 years 3 years
Expected volatility 90.01% 78.58%


Option-pricing models require the use of highly subjective
estimates and assumptions including the expected stock price
volatility. Changes in the underlying assumptions can
materially affect the fair value estimates and therefore, in
management`s opinion, existing models do not necessarily
provide reliable measure of the fair value of the Company`s
stock options.

F-10

<PAGE>

MIV THERAPEUTICS INC.
(A development stage company)

Notes to Consolidated Financial Statements
August 31, 2005
(Unaudited - Prepared by Management)
(EXPRESSED IN U.S. DOLLARS)
- --------------------------------------------------------------------------------


3. STOCKHOLDERS` EQUITY (continued)

(c) Stock Options (continued)

Summary of employee stock options information for the period
ended August 31, 2005 is as follows:
<TABLE>
--------------------------------------------------------------------------------------------
Weighted Average
Shares Exercise Price
--------------------------------------------------------------------------------------------

<S> <C> <C>
Options outstanding, May 31, 2005 7,780,000 0.35

Options granted 200,000 0.30
--------------------------------------------------------------------------------------------

Options outstanding, August 31, 2005 7,980,000 0.34
============================================================================================

The following summarizes information about the stock options
outstanding and exercisable at August 31, 2005:

Options Outstanding Options Exercisable
Weighted
Average Weighted Weighted
Range of Number of Remaining Average Number of Average
Exercise options Contractual Exercise options Exercise
Prices Outstanding Life (yr) Price Exercisable Price
--------------------------------------------------------------------------------------------------

$ 0.17 950,000 1.68 $ 0.17 950,000 $ 0.17
$ 0.20 1,400,000 4.45 $ 0.20 1,400,000 $ 0.20
$ 0.21 500,000 2.64 $ 0.21 500,000 $ 0.21
$ 0.30 3,120,000 3.98 $ 0.30 3,120,000 $ 0.30
$ 0.40 300,000 4.26 $ 0.40 230,000 $ 0.40
$ 0.50 550,000 2.03 $ 0.50 550,000 $ 0.50
$ 0.55 650,000 2.25 $ 0.55 650,000 $ 0.55
$ 1.00 510,000 1.28 $ 1.00 510,000 $ 1.00
--------------------------------------------------------------------------------------------------
$0.17 - $1.00 7,980,000 3.27 $ 0.34 7,910,000 $ 0.34
==================================================================================================
</TABLE>

F-11

<PAGE>

MIV THERAPEUTICS INC.
(A development stage company)

Notes to Consolidated Financial Statements
August 31, 2005
(Unaudited - Prepared by Management)
(EXPRESSED IN U.S. DOLLARS)
- --------------------------------------------------------------------------------


3. STOCKHOLDERS` EQUITY (continued)

(d) Pro-forma Disclosure

Had compensation expense for the Company`s stock-based
compensation plans been determined under SFAS No. 123, based
on the fair market value at the grant dates, the Company`s
pro-forma net loss and pro-forma net loss per share would have
been reflected as follows:
<TABLE>

---------------------------------------------------------------------------------------------------
August 31 August 31
2005 2004
---------------------------------------------------------------------------------------------------
<S> <C> <C>
Net loss, as reported $ (1,415,470) $ (858,853)

Add: Stock-based employee compensation expense
included in reported net loss above, net of related
tax effects 96,243 -

Deduct: Total stock-based employee compensation
expense determined under fair value based method for
all awards, net of related tax effects (134,414) -
---------------------------------------------------------------------------------------------------

Pro-forma loss for the year $(1,453,641) $(858,853)
===================================================================================================
Pro-forma basic and diluted loss per share (0.02) (0.02)
===================================================================================================
</TABLE>

[dosco12]

07.11.2005 15:19
MIV Therapeutics Inc.: kaufen (Invest Inside)


Die Eigentümer der gemäß der "Regulation S" ausgegebenen Stammaktien, die an der Berliner Börse unter der WKN 911285 handelbar seien, hätten ab sofort die Möglichkeit, ihre Aktien im Oktober 2006 bei der US-Börsenaufsichtsbehörde registrieren zu lassen. Als Folge könnten die Reg S-Aktien dann auch in New York veräußert werden. Das Unternehmen habe diese Vorgehensweise gewählt, um sicherzustellen, dass die Rechte ihrer europäischen Aktionäre denen ihrer nordamerikanischen Aktionäre entsprechen würden. Die Reg S-Aktien würden aktuell rund 50% unter dem Kurs der in Frankfurt handelbaren "normalen Aktien" notieren. Es sei davon auszugehen, dass durch das Registrierungsrecht etwaige zwischen den beiden Aktien bestehende Kursunterschiede beseitigt würden.

[dosco12]

911285 nun offensichtlich auch in frankfurt handelbar...

und noch 11 monate bis 798618 = 911285 !!!

gruß,
dosco

[dosco12]

hi,
911285 = 798618

habe gestern neue infos bekommen.

a. dass man hart an der smt übernahme arbeitet. das wird sicher nicht mehr lange dauern. wurde ja auch zeit!
dadurch wirds einen ordentlichen schuss tun... denn dadurch wird man automatisch echte umsatze haben und nicht erst 2007!

b. hatte wieder wegen des umtausches gebohrt und die info erhalten: nein, wir kaufen die nicht zurück. befründung: der markt ist frei; es wird doch bald umgetauscht. man ist eben ein dummkopf, wenn man in berlin zu solchen kursen verkauft.

c. habe noch einmal angefragt wie das ganz genau mit der registrierung laufen wird, d.h. ob "vollautomatisch" oder ob der aktionär doch irgendetwas einreichen/beantragen muss.


gruß,
dosco